Workflow
海王英特龙(08329) - 2021 - 中期财报
NEP INTERLONGNEP INTERLONG(HK:08329)2021-08-12 13:30

Revenue and Profitability - Revenue for the six months ended June 30, 2021, was RMB 391,194,000, a decrease of 15% compared to RMB 459,546,000 for the same period in 2020[8] - Gross profit for the six months ended June 30, 2021, was RMB 185,303,000, down 22.6% from RMB 239,800,000 in the prior year[8] - Profit and total comprehensive income for the period was RMB 22,685,000, an increase of 17.5% compared to RMB 19,254,000 for the same period in 2020[10] - Basic and diluted earnings per share for the six months was RMB 1.17 cents, compared to RMB 1.09 cents for the same period in 2020[10] - Profit before taxation for the six months was RMB 26,032,000, an increase of 16.2% compared to RMB 22,306,000 in the prior year[8] - The company reported a consolidated profit before taxation of RMB 26,032,000, up from RMB 22,306,000 in 2020, representing an increase of 16.2%[121] - For the three months ended June 30, 2021, the profit attributable to owners of the Company was approximately RMB 3,999,000, compared to RMB 8,932,000 for the same period in 2020, representing a decrease of 55.2%[150] - For the six months ended June 30, 2021, the profit attributable to owners of the Company was approximately RMB 19,647,000, compared to RMB 18,250,000 for the same period in 2020, representing an increase of 7.7%[150] Expenses and Costs - Selling and distribution expenses decreased significantly to RMB 121,177,000 for the six months ended June 30, 2021, from RMB 168,634,000 in 2020, a reduction of 28%[8] - Administrative expenses increased to RMB 34,465,000 for the six months ended June 30, 2021, compared to RMB 29,699,000 in the previous year, reflecting an increase of 16.5%[8] - Staff costs, including salaries and benefits, increased to RMB 32,845 for the six months ended June 30, 2021, from RMB 22,762 in 2020, reflecting a rise of 44.3%[138] - Research and development costs for the six months ended June 30, 2021, were RMB 11,402, up from RMB 10,375 in 2020, showing an increase of 9.9%[138] Assets and Liabilities - As of June 30, 2021, total assets amounted to RMB 935,317,000, an increase from RMB 908,615,000 as of December 31, 2020, reflecting a growth of approximately 2.5%[14] - Current liabilities increased to RMB 310,658,000 from RMB 212,267,000, representing a rise of about 46.3%[14] - Net current assets decreased to RMB 386,327,000 from RMB 597,084,000, indicating a decline of approximately 35.3%[14] - The company's total equity reached RMB 905,231,000, up from RMB 895,672,000, marking an increase of about 1.6%[16] - Trade and other payables increased to RMB 244,388,000 from RMB 179,509,000, reflecting a growth of about 36.1%[14] - Total reportable segment assets increased to RMB 1,393,708,000 in 2021 from RMB 1,251,998,000 in 2020, indicating a growth of 11.3%[121] - The consolidated total liabilities rose to RMB 340,744, compared to RMB 225,210 at the end of 2020, indicating an increase of about 51.1%[124] Cash Flow - Net cash used in operating activities was RMB 65,036,000 in H1 2021, compared to a cash generation of RMB 70,854,000 in H1 2020[22] - Net cash outflow on acquisition of a subsidiary amounted to RMB 63,683,000, with total cash used in investing activities reaching RMB 64,412,000 in H1 2021[24] - Cash and cash equivalents at the end of the period were RMB 261,956,000, an increase from RMB 224,030,000 at the end of H1 2020[24] - Net cash used in financing activities was RMB 20,481,000 in H1 2021, compared to RMB 3,510,000 in H1 2020, indicating a significant increase in cash outflow[24] - The net decrease in cash and cash equivalents for the period was RMB 149,929,000, a slight improvement from a decrease of RMB 160,181,000 in H1 2020[24] Segment Information - The Group operates in two reportable segments: manufacturing and selling of medicines, and sales and distribution of medicines and healthcare products[39] - Reportable segment revenue for the six months ended June 30, 2021, was RMB 412,103,000, a decrease of 12.8% compared to RMB 472,938,000 in 2020[121] - Revenue from external customers increased to RMB 233,766,000 in 2021 from RMB 199,482,000 in 2020, representing a growth of 17.2%[121] - Reportable segment profit (adjusted EBT) rose significantly to RMB 26,391,000 in 2021, up from RMB 23,365,000 in 2020, marking an increase of 8.7%[121] Acquisitions and Investments - On June 1, 2021, the Group completed the acquisition of 51% equity interest in Beijing Neptunus Zhongxin Pharmaceutical Co., Limited for a total consideration of RMB 76,500,000[196] - The goodwill arising from the acquisition of Neptunus Zhongxin was approximately RMB 90,163,000[197] - The Group made a payment of RMB 769,000 for lease liabilities in H1 2021, which was not present in H1 2020[24] - The Group purchased property, plant, and equipment amounting to approximately RMB 7,641,000 during the Reporting Period, a decrease from RMB 14,444,000 in 2020[150] Financial Reporting and Standards - The Group is currently assessing the impact of new and amended HKFRSs on its financial position and results for the first year of application, with expectations of no material impact[30] - The Group adopted new HKFRSs effective from January 1, 2021, including amendments related to Covid-19 rent concessions and interest rate benchmark reforms[30] - The interim financial statements are unaudited, indicating a preliminary assessment of the Group's financial performance[28] - The Group's financial statements are prepared on a historical cost basis and presented in Renminbi (RMB)[28]